The continuum of serous tumors of low malignant potential and low-grade serous carcinomas of the ovary

Disease Markers

Volumn 23, Issue 5-6, 2007, Pages 377-387

  Wong, Kwong Kwok ^a   Gershenson, David ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

B Raf; Genomics; K Ras; Ki 67; Low malignant potential; Low grade serous ovarian carcinoma; p53

Indexed keywords

ANTIINFECTIVE AGENT; CHECKPOINT KINASE 2; PROTEIN P53;

CANCER GRADING; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL OBSERVATION; CLINICAL TRIAL; DISEASE ASSOCIATION; GENE EXPRESSION PROFILING; GENE MUTATION; HORMONAL THERAPY; HUMAN; OVARY CANCER; PRIORITY JOURNAL; REVIEW;

EID: 36448982529     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.1155/2007/204715     Document Type: Review

References (79)

1. Classification and staging of malignant tumours in the female pelvis, Acta Obstet Gynecol Scand 50 (1971), 1-7.
2. D.S. Alberts, P.Y. Liu, E.V. Hannigan, R. O'Toole, S.D. Williams, J.A. Young, E.W. Franklin, D.L. Clarke-Pearson, V.K. Malviya and B. DuBeshter, Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage iii ovarian cancer, N Engl J Med 335 (1996), 1950-1955.
3. R.R. Barakat, I. Benjamin, J.L. Lewis Jr., P.E. Saigo, J.P. Curtin and W.J. Hoskins, Platinum-based chemotherapy for advanced-stage serous ovarian carcinoma of low malignant potential, Gynecol Oncol 59 (1995), 390-393.
4. D.R. Barnhill, R.J. Kurman, M.F. Brady, G.A. Omura, E. Yordan, F.T. Given, P.R. Kucera and L.D. Roman, Preliminary analysis of the behavior of stage i ovarian serous tumors of low malignant potential: A gynecologic oncology group study, J Clin Oncol 13 (1995), 2752-2756.
5. D.A. Bell, M.A. Weinstock and R.E. Scully, Peritoneal implants of ovarian serous borderline tumors. Histologic features and prognosis, Cancer 62 (1988), 2212-2222.
6. D.A. Bell, T.A. Longacre, J. Prat, E.C. Kohn, R.A. Soslow, L.H. Ellenson, A. Malpica, M.H. Stoler and R.J. Kurman, Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: Workshop perspectives, Hum Pathol 35 (2004), 934-948.
7. T. Bonome, J.Y. Lee, D.C. Park, M. Radonovich, C. Pise-Masison, J. Brady, G.J. Gardner, K. Hao, W.H. Wong, J.C. Barrett, K.H. Lu, A.K. Sood, D.M. Gershenson, S.C. Mok and M.J. Birrer, Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary, Cancer Res 65 (2005), 10602-10612.
8. D.G. Bostwick, H.D. Tazelaar, S.C. Ballon, M.R. Hendrickson and R.L. Kempson, Ovarian epithelial tumors of borderline malignancy. A clinical and pathologic study of 109 cases, Cancer 58 (1986), 2052-2065.
9. R.T. Burks, M.E. Sherman and R.J. Kurman, Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors, Am J Surg Pathol 20 (1996), 1319-1330.
10. R.F. Caduff, S.M. Svoboda-Newman, A.W. Ferguson, C.M. Johnston and T.S. Frank, Comparison of mutations of ki-ras and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors, Am J Surg Pathol 23 (1999), 323-328.
11. J.T. Chambers, M.J. Merino, E.I. Kohorn and P.E. Schwartz, Borderline ovarian tumors, Am J Obstet Gynecol 159 (1988), 1088-1094.
12. M.A. Crispens, D. Bodurka, M. Deavers, K. Lu, E.G. Silva and D.M. Gershenson, Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential, Obstet Gynecol 99 (2002), 3-10.
13. C. Cybulski, T. Huzarski, B. Gorski, B. Masojc, M. Mierzejewski, T. Debniak, B. Gliniewicz, J. Matyjasik, E. Zlowocka, G. Kurzawski, A. Sikorski, M. Posmyk, M. Szwiec, R. Czajka, S.A. Narod and J. Lubinski, A novel founder chek2 mutation is associated with increased prostate cancer risk, Cancer Res 64 (2004), 2677-2679.
14. M.T. Deavers, D.M. Gershenson, G. Tortolero-Luna, A. Malpica, K.H. Lu and E.G. Silva, Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: A study of 99 advanced stage cases, Am J Surg Pathol 26 (2002), 1129-1141.
15. J. Diebold, F. Seemuller and U. Lohrs, K-ras mutations in ovarian and extraovarian lesions of serous tumors of borderline malignancy, Lab Invest 83 (2003), 251-258.
16. M.K. Dodson, L.C. Hartmann, W.A. Cliby, K.A. DeLacey, G.L. Keeney, S.R. Ritland, J.Q. Su, K.C. Podratz and R.B. Jenkins, Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas, Cancer Res 53 (1993), 4456-4460.
17. J.H. Eichhorn, D.A. Bell, R.H. Young and R.E. Scully, Ovarian serous borderline tumors with micropapillary and cribriform patterns: A study of 40 cases and comparison with 44 cases without these patterns, Am J Surg Pathol 23 (1999), 397-409.
18. R. Fauvet, J. Boccara, C. Dufournet, E. David-Montefiore, C. Poncelet and E. Darai, Restaging surgery for women with borderline ovarian tumors: Results of a french multicenter study, Cancer 100 (2004), 1145-1151.
19. K.M. Feeley and M. Wells, Precursor lesions of ovarian epithelial malignancy, Histopathology 38 (2001), 87-95.
20. M.G. Fort, V.K. Pierce, P.E. Saigo, W.J. Hoskins and J.L. Lewis Jr., Evidence for the efficacy of adjuvant therapy in epithelial ovarian tumors of low malignant potential, Gynecol Oncol 32 (1989), 269-272.
21. D.M. Gershenson, Clinical management potential tumours of low malignancy, Best Pract Res Clin Obstet Gynaecol 16 (2002), 513-527.
22. D.M. Gershenson and E.G. Silva, Serous ovarian tumors of low malignant potential with peritoneal implants, Cancer 65 (1990), 578-585.
23. D.M. Gershenson, E.G. Silva, L. Levy, T.W. Burke, J.K. Wolf and C. Tornos, Ovarian serous borderline tumors with invasive peritoneal implants, Cancer 82 (1998), 1096-1103.
24. D.M. Gershenson, E.G. Silva, G. Tortolero-Luna, C. Levenback, M. Morris and C. Tornos, Serous borderline tumors of the ovary with noninvasive peritoneal implants, Cancer 83 (1998), 2157-2163.
25. D.M. Gershenson, C.C. Sun, K.H. Lu, R.L. Coleman, A.K. Sood, A. Malpica, M.T. Deavers, E.G. Silva and D.C. Bodurka, Clinical behavior of stage ii-iv low-grade serous carcinoma of the ovary, Obstet Gynecol 108 (2006), 361-368.
26. C.B. Gilks, Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data, Int J Gynecol Pathol 23 (2004), 200-205.
27. C.B. Gilks, B.C. Vanderhyden, S. Zhu, M. van de Rijn and T.A. Longacre, Distinction between serous tumors of low malignant potential and serous carcinomas based on global mrna expression profiling, Gynecol Oncol 96 (2005), 684-694.
28. J. Gu, L.M. Roth, C. Younger, H. Michael, F.W. Abdul-Karim, S. Zhang, T.M. Ulbright, J.N. Eble and L. Cheng, Molecular evidence for the independent origin of extra-ovarian papillary serous tumors of low malignant potential, J Natl Cancer Inst 93 (2001), 1147-1152.
29. C.J. Haas, J. Diebold, A. Hirschmann, H. Rohrbach and U. Lohrs, In serous ovarian neoplasms the frequency of ki-ras mutations correlates with their malignant potential, Virchows Arch 434 (1999), 117-120.
30. C.C. Harris, The 1995 walter hubert lecture-molecular epidemiology of human cancer: Insights from the mutational analysis of the p53 tumour-suppressor gene, Br J Cancer 73 (1996), 261-269.
31. K. Helou, H. Padilla-Nash, D. Wangsa, E. Karlsson, L. Osterberg, P. Karlsson, T. Ried and T. Knutsen, Comparative genome hybridization reveals specific genomic imbalances during the genesis from benign through borderline to malignant ovarian tumors, Cancer Genet Cytogenet 170 (2006), 1-8.
32. M.P. Hopkins and G.W. Morley, The second-look operation and surgical reexploration in ovarian tumor of low malignant potential, Obstet Gynecol 74 (1989), 375-378.
33. C.Y. Hsu, R. Bristow, M.S. Cha, B.G. Wang, C.L. Ho, R.J. Kurman, T.L. Wang and M. Shih Ie, Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas, Clin Cancer Res 10 (2004), 6432-6436.
34. R. Hutson, J. Ramsdale and M. Wells, P53 protein expression in putative precursor lesions of epithelial ovarian cancer, Histopathology 27 (1995), 367-371.
35. H. Iwabuchi, M. Sakamoto, H. Sakunaga, Y.Y. Ma, M.L. Carcangiu, D. Pinkel, T.L. Yang-Feng and J.W. Gray, Genetic analysis of benign, low-grade, and high-grade ovarian tumors, Cancer Res 55 (1995), 6172-6180.
36. A.A. Jazaeri, K. Lu, R. Schmandt, C.P. Harris, P.H. Rao, C. Sotiriou, G.V. Chandramouli, D.M. Gershenson and E.T. Liu, Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma, Mol Carcinog 36 (2003), 53-59.
37. J. Kaern, C.G. Trope and V.M. Abeler, A retrospective study of 370 borderline tumors of the ovary treated at the norwegian radium hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities, Cancer 71 (1993), 1810-1820.
38. M. Kiechle, A. Jacobsen, U. Schwarz-Boeger, J. Hedderich, J. Pfisterer and N. Arnold, Comparative genomic hybridization detects genetic imbalances in primary ovarian carcinomas as correlated with grade of differentiation, Cancer 91 (2001), 534-540.
39. L.M. Kmet, L.S. Cook and A.M. Magliocco, A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors, Cancer 97 (2003), 389-404.
40. W. Kolch, Meaningful relationships: The regulation of the ras/raf/mek/erk pathway by protein interactions, Biochem J 351 Pt 2 (2000), 289-305.
41. J.F. Leake, J.L. Currie, N.B. Rosenshein and J.D. Woodruff, Long-term follow-up of serous ovarian tumors of low malignant potential, Gynecol Oncol 47 (1992), 150-158.
42. P.S. Lin, D.M. Gershenson, M.W. Bevers, K.R. Lucas, T.W. Burke and E.G. Silva, The current status of surgical staging of ovarian serous borderline tumors, Cancer 85 (1999), 905-911.
43. T.A. Longacre, J.K. McKenney, H.D. Tazelaar, R.L. Kempson and M.R. Hendrickson, Ovarian serous tumors of low malignant potential (borderline tumors): Outcome-based study of 276 patients with long-term (> or = 5-year) follow-up, Am J Surg Pathol 29 (2005), 707-723.
44. K.H. Lu, D.A. Bell, W.R. Welch, R.S. Berkowitz and S.C. Mok, Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors, Cancer Res 58 (1998), 2328-2330.
45. A. Malpica, M.T. Deavers, K. Lu, D.C. Bodurka, E.N. Atkinson, D.M. Gershenson and E.G. Silva, Grading ovarian serous carcinoma using a two-tier system, Am J Surg Pathol 28 (2004), 496-504.
46. S. Matsuoka, M. Huang and S.J. Elledge, Linkage of atm to cell cycle regulation by the chk2 protein kinase, Science 282 (1998), 1893-1897.
47. D. Mayr, A. Hirschmann, U. Lohrs and J. Diebold, Kras and braf mutations in ovarian tumors: A comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants, Gynecol Oncol (2006), in press.
48. W.T. McCaughey, M.E. Kirk, W. Lester and I. Dardick, Peritoneal epithelial lesions associated with proliferative serous tumours of ovary, Histopathology 8 (1984), 195-208.
49. W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, K.Y. Look, D.L. Clarke-Pearson and M. Davidson, Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: A phase iii randomized trial in patients with suboptimal stage iii/iv ovarian cancer (from the gynecologic oncology group), Semin Oncol 23 (1996), 40-47.
50. H.G. Meerpohl, W. Sauerbrei, H. Kuhnle, M. Schumacher and A. Pfleiderer, Randomized study comparing carboplatin/cyclophosphamide and cisplatin/ cyclophosphamide as first-line treatment in patients with stage iii/iv epithelial ovarian cancer and small volume disease. German ovarian cancer study group (goca), Gynecol Oncol 66 (1997), 75-84.
51. I. Meinhold-Heerlein, D. Bauerschlag, F. Hilpert, P. Dimitrov, L.M. Sapinoso, M. Orlowska-Volk, T. Bauknecht, T.W. Park, W. Jonat, A. Jacobsen, J. Sehouli, J. Luttges, M. Krajewski, S. Krajewski, J.C. Reed, N. Arnold and G.M. Hampton, Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential, Oncogene 24 (2005), 1053-1065.
52. H. Michael and L. M. Roth, Invasive and noninvasive implants in ovarian serous tumors of low malignant potential, Cancer 57 (1986), 1240-1247.
53. F.M. Muggia, P.S. Braly, M.F. Brady, G. Sutton, T.H. Niemann, S.L. Lentz, R.D. Alvarez, P.R. Kucera and J.M. Small, Phase iii randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage iii or iv ovarian cancer: A gynecologic oncology group study, J Clin Oncol 18 (2000), 106-115.
54. J.G. Nation and G.V. Krepart, Ovarian carcinoma of low malignant potential: Staging and treatment, Am J Obstet Gynecol 154 (1986), 290-293.
55. J.P. Neijt, S.A. Engelholm, M.K. Tuxen, P.G. Sorensen, M. Hansen, C. Sessa, C.A. de Swart, F.R. Hirsch, B. Lund and H.C. van Houwelingen, Exploratory phase iii study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer, J Clin Oncol 18 (2000), 3084-3092.
56. C.J. O'Neill, M.T. Deavers, A. Malpica, H. Foster and W.G. McCluggage, An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: Significantly higher expression of p53, mib1, bcl2, her-2/neu, and c-kit in high-grade neoplasms, Am J Surg Pathol 29 (2005), 1034-1041.
57. B.H. Ortiz, M. Ailawadi, C. Colitti, M.G. Muto, M. Deavers, E.G. Silva, R.S. Berkowitz, S.C. Mok and D.M. Gershenson, Second primary or recurrence? Comparative patterns of p53 and k-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors, Cancer Res 61 (2001), 7264-7267.
58. V. Ouellet, D.M. Provencher, C.M. Maugard, C. Le Page, F. Ren, C. Lussier, J. Novak, B. Ge, T.J. Hudson, P.N. Tonin and A.M. Mes-Masson, Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling, Oncogene 24 (2005), 4672-4687.
59. R.F. Ozols, B.N. Bundy, B.E. Greer, J.M. Fowler, D. Clarke-Pearson, R.A. Burger, R.S. Mannel, K. DeGeest, E.M. Hartenbach and R. Baergen, Phase iii trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage iii ovarian cancer: A gynecologic oncology group study, J Clin Oncol 21 (2003), 3194-3200.
60. T. Pejovic, C.S. Iosif, F. Mitelman and S. Heim, Karyotypic characteristics of borderline malignant tumors of the ovary: Trisomy 12, trisomy 7, and r(1) as nonrandom features, Cancer Genet Cytogenet 92 (1996), 95-98.
61. G.G. Rao, E. Skinner, P.A. Gehrig, L.R. Duska, R.L. Coleman and J.O. Schorge, Surgical staging of ovarian low malignant potential tumors, Obstet Gynecol 104 (2004), 261-266.
62. P. Russell and H. Merkur, Proliferating ovarian "Epithelial" Tumours: A clinico-pathological analysis of 144 cases, Aust N Z J Obstet Gynaecol 19 (1979), 45-51.
63. D.R. Schwartz, S.L. Kardia, K.A. Shedden, R. Kuick, G. Michailidis, J.M. Taylor, D.E. Misek, R. Wu, Y. Zhai, D.M. Darrah, H. Reed, L.H. Ellenson, T.J. Giordano, E.R. Fearon, S.M. Hanash and K.R. Cho, Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas, Cancer Res 62 (2002), 4722-4729.
64. J.D. Seidman and R.J. Kurman, Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases, Am J Surg Pathol 20 (1996), 1331-1345.
65. S.F. Serov, R.E. Scully and L.H. Sobin, "International histological classification of tumours",World Health Organization, Geneva, Switzerland, 1973, pp. 17-54.
66. M. Shih Ie and R.J. Kurman, Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis, Am J Pathol 164 (2004), 1511-1518.
67. N.L. Sieben, P. Macropoulos, G.M. Roemen, S.M. Kolkman-Uljee, G. Jan Fleuren, R. Houmadi, T. Diss, B. Warren, M. Al Adnani, A.P. De Goeij, T. Krausz and A.M. Flanagan, In ovarian neoplasms, braf, but not kras, mutations are restricted to low-grade serous tumours, J Pathol 202 (2004), 336-340.
68. E.G. Silva, D.M. Gershenson, A. Malpica and M. Deavers, The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent, Am J Surg Pathol 30 (2006), 1367-1371.
69. G. Singer, R.J. Kurman, H.W. Chang, S.K. Cho and M. Shih Ie, Diverse tumorigenic pathways in ovarian serous carcinoma, Am J Pathol 160 (2002), 1223-1228.
70. G. Singer, M. Shih Ie, A. Truskinovsky, H. Umudum and R.J. Kurman, Mutational analysis of k-ras segregates ovarian serous carcinomas into two types: Invasive mpsc (low-grade tumor) and conventional serous carcinoma (high-grade tumor), Int J Gynecol Pathol 22 (2003), 37-41.
71. G. Singer, R. Oldt, 3rd, Y. Cohen, B.G. Wang, D. Sidransky, R.J. Kurman and M. Shih Ie, Mutations in braf and kras characterize the development of low-grade ovarian serous carcinoma, J Natl Cancer Inst 95 (2003), 484-486.
72. G. Singer, R. Stohr, L. Cope, R. Dehari, A. Hartmann, D.F. Cao, T.L. Wang, R.J. Kurman and M. Shih Ie, Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: A mutational analysis with immunohistochemical correlation, Am J Surg Pathol 29 (2005), 218-224.
73. B.M. Slomovitz, T.A. Caputo, H.F. Gretz, 3rd, K. Economos, D.V. Tortoriello, P.W. Schlosshauer, R.N. Baergen, C. Isacson and R.A. Soslow, A comparative analysis of 57 serous borderline tumors with and without a noninvasive micropapillary component, Am J Surg Pathol 26 (2002), 592-600.
74. D.D. Snider, G.C. Stuart, J.G. Nation and D.I. Robertson, Evaluation of surgical staging in stage i low malignant potential ovarian tumors, Gynecol Oncol 40 (1991), 129-132.
75. J. Szymanska-Pasternak, A. Szymanska, K. Medrek, E.N. Imyanitov, C. Cybulski, B. Gorski, P. Magnowski, I. Dziuba, K. Gugala, B. Debniak, S. Gozdz, A.P. Sokolenko, N.Y. Krylova, O.S. Lobeiko, S.A. Narod and J. Lubinski, Chek2 variants predispose to benign, borderline and low-grade invasive ovarian tumors, Gynecol Oncol 102 (2006), 429-431.
76. H.C. Taylor, Malignant and semimalignant tumors of the ovary, Surgery, Gynecology & Obstetrics 48 (1929), 206-230.
77. M.G. Teneriello, M. Ebina, R.I. Linnoila, M. Henry, J.D. Nash, R.C. Park and M.J. Birrer, P53 and ki-ras gene mutations in epithelial ovarian neoplasms, Cancer Res 53 (1993), 3103-3108.
78. N.G. Wolf, C. Farver, F.W. Abdul-Karim and S. Schwartz, Analysis of microsatellite instability and x-inactivation in ovarian borderline tumors lacking numerical abnormalities by comparative genomic hybridization, Cancer Genet Cytogenet 145 (2003), 133-138.
79. R. Yazigi, J. Sandstad and A. K. Munoz, Primary staging in ovarian tumors of low malignant potential, Gynecol Oncol 31 (1988), 402-408.